Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (8631)	6/5/2003 5:27:30 PM
From: Biomaven	Respond to of 52153

The 70 top gainers today: Net% Symbol Title 102.5 TGEN Targeted Genetics Corporation (UPC) 34.87 ELI Elite Pharma Inc {D15} 24.31 GERN Geron Corporation (UPC) 24.13 GNBT Generex Biotechnology Corporation 22.36 TKTX Transkaryotic Therapies, Inc. 21.95 NPSP NPS Pharmaceuticals, Inc. 21.25 DMI Depomed Inc Sc {D15} 20.3 LIFC LifeCell Corporation 19.71 PVLS Provalis plc 19.1 ICOS ICOS Corporation 18.43 CYTO Cytogen Corporation (UPC) 18 DYAX Dyax Corporation 17.87 CRIS Curis, Inc. (UPC) 17.1 CVTX CV Therapeutics, Inc. 17.08 ONXX ONYX Pharmaceuticals, Inc. 16.75 XNVA Xenova Group plc (UPC) 16.57 EMIS Emisphere Technologies, Inc. 16.07 NPRO NaPro BioTherapeutics, Inc. 15.83 ABGX Abgenix, Inc. 15.52 BMRN BioMarin Pharmaceutical Inc. 14.76 CTE Cardiotech Intl {D15} 14.7 STEM StemCells, Inc. (UPC) 14.52 CLPA Cell Pathways, Inc. 14.05 OSIP OSI Pharmaceuticals Inc. 14.04 AXYX Axonyx, Inc. 14.04 VLGC ViroLogic, Inc. 13.69 ALXN Alexion Pharmaceuticals, Inc. 13.59 INCY Incyte Corporation 13.44 LGND Ligand Pharmaceuticals Incorporated 13.3 BPUR Biopure Corporation (UPC) 13.25 DSCO Discovery Laboratories Inc. 12.9 VRA Viragen Inc {D15} 12.79 IPXL Impax Laboratories, Inc. 12.62 AMLN Amylin Pharmaceuticals, Inc. 11.76 ASTM Aastrom Biosciences, Inc. 11.73 NEXM NexMed, Inc. 11.57 PDLI Protein Design Labs, Inc. 11.45 CBST Cubist Pharmaceuticals, Inc. 11.45 EXEL Exelixis, Inc. 11 MOGN MGI PHARMA, Inc. 10.94 VXGN VaxGen, Inc. (UPC) 10.68 GORX Innovative Companies Inc. 10.66 SUPG SuperGen, Inc. 9.93 NBIX Neurocrine Biosciences, Inc. 9.7 CTIC Cell Therapeutics, Inc. 9.5 ARQL ArQule, Inc. 9.44 ELN Elan Cp Plc Adr {D20} 9.37 DATA DataTrak International, Inc. 9.33 GLFD Guilford Pharmaceuticals Inc. 9.1 NRGN Neurogen Corporation 8.94 HEPH Hollis-Eden Pharmaceuticals, Inc. (UPC) 8.94 VITX V. I. Technologies, Inc. 8.75 CYPB Cypress Bioscience Inc. 8.49 VPHM ViroPharma Incorporated 8.46 VRTX Vertex Pharmaceuticals Incorporated 8.42 DUSA DUSA Pharmaceuticals, Inc. 8.13 IVGN Invitrogen Corporation 7.8 HGSI Human Genome Sciences, Inc. 7.72 NAII Natural Alternatives International, Inc. 7.64 ARIA ARIAD Pharmaceuticals, Inc. 7.5 NTOL Natrol, Inc. 7.47 KOSN Kosan Biosciences Incorporated 7.44 DCRN Diacrin, Inc. 7.41 ALT Alteon Inc {D15} 7.38 CGEN Compugen Ltd. 7.26 CRA Celera Genomics {D20} 7.25 BRL Barr Labs Inc {D20} 7.22 ENZ Enzo Biochem Inc {D20} 7.16 CELG Celgene Corporation

To: Biomaven who wrote (8631)	6/5/2003 5:54:23 PM
From: Ian@SI	Read Replies (2) \| Respond to of 52153

Clearly there is some froth in the air - not quite sure how much froth makes a full-fledged bubble, though. <g> Isn't part of this a McLellan<sp?> "dividend"? I believe the market is discarding part of the FDA risk premium. I don't think that IMCLE would have responded the way it has to the Erbitux BLA announcement if Velcade hadn't been approved so rapidly by McLellan's FDA. Now up almost $14!!!

To: Biomaven who wrote (8631)	6/5/2003 5:58:14 PM
From: Icebrg	Read Replies (2) \| Respond to of 52153

>>Nobody rings a bell at the top. >> I know from my own experience that this is perfectly true. Still, I think that the important thing is to have mentally sorted out what the exit strategy should be and just execute it. I am pretty careful to rebalance the portfolio when I feel that one security grows too much. I have "lost" a fair amount on Elan because of this over the last couple of days. A strategy I would rather like to employ is to sell after a share has lost x (perhaps 5 or 10 depending on preferences) percent from its most recent high. If properly executed this should ensure, that there are no major opportunity losses, giving some leeway to the fact that these things tend to move along much further than what we in our wisdom think is reasonable. With such a strategy there will of course not be any protection against an implosion-like movement by all stocks at the same time, but most of the other scenarios will be covered. One of my problems working from Sweden is that my transactions costs are very high. Not only on the actual buying and selling but also the very bad exchange rates my bank is giving me. So, I am rather reluctant to "trade" it it at all is possible. Erik